- Eli Lilly (LLY -0.3%) and development partner Boehringer Ingelheim announce positive top-line results from two Phase 3 trials of empagliflozin as a treatment for type 2 diabetes.
- In a two-year 1,545-patient study comparing the safety and efficacy of empagliflozin with glimepiride each in combination with metformin, at 104 weeks patients in the empagliflozin cohort had significantly greater reductions in A1C, body weight and systolic and diastolic blood pressure from baseline compared to the glimepiride cohort. There were also significantly fewer hypoglycemic events in the empagliflozin group.
- In a 52-week placebo-controlled study of obese inadequately controlled type 2 diabetes patients on multiple daily insulin injections with or without metformin, empagliflozin significantly reduced A1C levels from baseline compared to the control group. Patients in the test group lost an average of 2 kg of weight versus a 0.4 kg average gain in the placebo group.